Astellas Pharma | 4503

Stock Price
2,132.00
Daily Change
-19.00 -0.88%
Monthly
-7.30%
Yearly
53.88%
Q2 Forecast
2,052.05

EPS Reference Time Actual Consensus Previous
2026-04-27 FY2026Q4 AM 24.29 13.8 41.84
2026-02-04 FY2026Q3 AM 56.04 42.81 -54.55
2025-10-30 FY2026Q2 AM 44.22 27.83 20.06
2025-07-30 FY2026Q1 AM 38.22 24.13 21.00
2025-04-25 FY2025Q4 AM 41.84 -34.05 -18.55



Peers Price Chg Day Year Date
M3 1,588.50 -13.50 -0.84% -21.09% Jun/16
Kyowa Hakko Kirin 2,394.00 5.50 0.23% -4.09% Jun/16
Takeda 4,993.00 -95.00 -1.87% 15.15% Jun/16
Astellas Pharma 2,132.00 -19.00 -0.88% 53.88% Jun/16
Sumitomo Dainippon 1,486.00 67.50 4.76% 41.93% Jun/16
Shionogi 2,795.00 8.00 0.29% 11.42% Jun/16
Chugai Pharma 7,469.00 41.00 0.55% 0.09% Jun/16
Eisai 3,739.00 -82.00 -2.15% -7.22% Jun/16
Terumo 2,209.50 -27.50 -1.23% -14.64% Jun/16
Daiichi Sankyo 2,506.00 -40.00 -1.57% -27.40% Jun/16

Indexes Price Day Year Date
JP225 69390 49.50 0.07% 80.06% Jun/16

Astellas Pharma traded at 2,132.00 this Tuesday June 16th, decreasing 19.00 or 0.88 percent since the previous trading session. Looking back, over the last four weeks, Astellas Pharma lost 7.30 percent. Over the last 12 months, its price rose by 53.88 percent. Looking ahead, we forecast Astellas Pharma to be priced at 2,052.05 by the end of this quarter and at 1,809.29 in one year, according to Trading Economics global macro models projections and analysts expectations.

Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.